Find information on thousands of medical conditions and prescription drugs.

Fluvoxamine

Fluvoxamine (sold as Luvox®, Faverin® and Fevarin®) is a selective serotonin reuptake inhibitor. It is used primarily to treat depression, anxiety and OCD. more...

Home
Diseases
Medicines
A
B
C
D
E
F
Captagon
Famohexal
Famotidine
Faslodex
Faslodex
Fasoracetam
Felbamate
Felbatol
Felodipine
Felypressin
Femara
Femara
Fempatch
Femring
Fenfluramine
Fenofibrate
Fentanyl
Fexofenadine
Filgrastim
Filipin
Finasteride
Fioricet
Fiorinal
Flagyl
Flarex
Flavoxate
Flecainide
Flexeril
Flomax
Flonase
Flovent
Floxuridine
Fluacizine
Flucloxacillin
Fluconazole
Flucytosine
Fludarabine
Fludrocortisone
Flumazenil
Flunisolide
Flunitrazepam
Fluocinonide
Fluohexal
Fluorometholone
Fluorouracil
Fluoxetine
Fluphenazine
Flurazepam
Flutamide
Fluticasone
Fluvastatin
Fluvoxamine
FML
Focalin
Folic acid
Follutein
Fomepizole
Formoterol
Fortamet
Fortovase
Fosamax
Fosinopril
Fosinoprilat
Fosmidomycin
Fosphenytoin
Frova
Frovatriptan
Frusehexal
Fulvestrant
Fumagillin
Furazolidone
Furosemide
Furoxone
Fusafungine
Fusidic acid
Fuzeon
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Although its effects are similar to other SSRIs, it acts on the body's neurochemistry differently. For this reason, fluvoxamine can be of benefit to patients who experience unusual or limiting side-effects from other antidepressants. Fluvoxamine also appears to cause fewer side-effects than other SSRIs, particularly in relation to loss of sex-drive.

Fluvoxamine has the shortest half-life of all the SSRIs. Its mean serum half-life is 15 hours after a single dose, and 17 to 22 hours after repeated doses.

Fluvoxamine causes many drug-drug interactions due to inhibition of metabolism mediated by several cytochrome P450 oxidases. Examples of substances that have higher serum levels when administered together with fluvoxamine include caffeine, clozapine, olanzapine, tricyclic antidepressants, diazepam, alprazolam, propranolol, warfarin and methadone.

Effective dosage

For depression and anxiety, dosage normally starts at 50 milligrams per day, rising to 100 milligrams after a few days. It may be raised after evaluation of the effects by a doctor.

Fluvoxamine is generally only effective for OCD at 150 milligrams and above, and dosages can reach 300 milligrams or more for some patients.

Historical Relevance

In 1999, fluvoxamine came under great public scrutiny after it was discovered that Eric Harris, one of the two teenaged shooters involved in the Columbine High School massacre, had been taking the drug as treatment for depression. Many immediately pointed fingers at fluvoxamine and its manufacturer Solvay Pharmaceuticals (which sells fluvoxamine under the widely known brandname Luvox), since Solvay's own clinical trials indicated the drug had the propensity to induce "mania" in 4% of the youth who took it. Solvay, while acknowledging the risks inherent in taking an SSRI medication like fluvoxamine, downplayed any role the drug may have had in the killings. The American Psychiatric Association (A.P.A.) took a similar stance; Rodrigo Munoz, M.D., President of the A.P.A., said: "Despite a decade of research, there is little valid evidence to prove a causal relationship between the use of anti-depressant medications and destructive behavior. On the other hand, there is ample evidence that undiagnosed and untreated mental illness exacts a heavy toll on those who suffer from these disorders as well as those around them." It was also pointed out by many that Luvox was often safer than the other SSRI medications available--for example, fluoxetine (Prozac) caused mania in 6% of youth tested on the drug (versus fluvoxamine's 4%). Nonetheless, the reputation of Luvox was irreparably damaged. Sales fell, and Solvay withdrew the medication from the U.S. market in 2002; the company maintains, however, that this move had nothing to do with the safety profile of the fluvoxamine, which they still sell in many countries around the world. In the United States, fluvoxamine can only be purchased generically.

Read more at Wikipedia.org


[List your site here Free!]


Fluvoxamine for the treatment of autistic disorders in adults - Tips from Other Journals
From American Family Physician, 3/1/97 by Grace Brooke Huffman

No more than 10 percent of children with autism become independent as adults; the remainder continue to struggle with social interaction, communication and activities. The etiology of this disorder is unknown, but a disruption in the serotonin neurotransmitter system is thought to be involved. McDougle and colleagues performed a 12-week double-blind, placebo-controlled trial to determine the effects of fluvoxamine on the behavior of adults with autism.

The study included 30 adults (27 men and three women) with symptoms that were at least moderately severe as defined by the global severity of illness rating on the Clinical Global Impression Scale. Each patient participated in an extensive behavior analysis, using a variety of assessment scales. In addition, each patient underwent a history and physical examination plus a variety of blood tests. Patients were randomly assigned to receive either placebo or fluvoxamine, starting at a dosage of 50 mg daily. The dosage was increased by 50 mg every three to four days, to a maximum dosage of 300 mg daily, until maximum response was obtained. After three weeks, a maximum dosage was achieved and the patient was maintained on this dosage for at least nine weeks. Reassessment of behavior occurred at four, eight and 12 weeks after the start of the study.

No significant differences in age, sex distribution, behavior or IQ scores were observed between the two groups at baseline. Beginning at week 4, there was an overall significant improvement in the fluvoxamine group that continued throughout the study period. Specifically, eight (53 percent) of the 15 patients in the fluvoxamine group were considered responders, versus none in the placebo group. When particular symptoms in individuals with autism were examined, fluvoxamine was found to be superior to placebo in all of the areas considered: repetitive thoughts and behaviors decreased, as did maladaptive behaviors and aggressive symptoms. Language usage also improved.

The authors conclude that fluvoxamine may be a useful treatment in adults with autism, because of its ability to improve behaviors as well as its low incidence of adverse effects.

McDougle CJ, et al. A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry 1996;53:1001-8.

COPYRIGHT 1997 American Academy of Family Physicians
COPYRIGHT 2004 Gale Group

Return to Fluvoxamine
Home Contact Resources Exchange Links ebay